• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    12/20/22 12:31:52 PM ET
    $ATNX
    $ATXI
    $AXLA
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNX alert in real time by email

    Gainers

    • Athenex (NASDAQ:ATNX) stock moved upwards by 41.4% to $0.19 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is 112.5 million, which is 9232.0% of its average full-day volume over the last 100 days. The company's market cap stands at $30.0 million.
    • Verona Pharma (NASDAQ:VRNA) stock rose 33.39% to $18.0. Trading volume for this security as of 12:30 EST is 12.3 million, which is 4920.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.3 billion.
    • Surrozen (NASDAQ:SRZN) shares rose 18.72% to $0.57. As of 12:30 EST, this security is trading at a volume of 2.9 million shares, making up 916.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $20.0 million.
    • Revelation Biosciences (NASDAQ:REVBU) stock increased by 16.71% to $0.28.
    • Vapotherm (NYSE:VAPO) stock increased by 16.24% to $2.2. As of 12:30 EST, this security is trading at a volume of 807.7K shares, making up 139.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $58.6 million.
    • Avenue Therapeutics (NASDAQ:ATXI) shares moved upwards by 15.57% to $1.33. The current volume of 92.1K shares is 2.1% of Avenue Therapeutics's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $6.3 million.

    Losers

    • Scopus BioPharma (NASDAQ:SCPS) stock fell 59.6% to $0.07 during Tuesday's regular session. As of 12:30 EST, this security is trading at a volume of 95.7K shares, making up 10.2% of its average full-day volume over the last 100 days. The company's market cap stands at $1.4 million.
    • Magenta Therapeutics (NASDAQ:MGTA) stock decreased by 53.98% to $0.38. Magenta Therapeutics's stock is trading at a volume of 3.6 million shares as of 12:30 EST. This is 411.4% of its average full-day volume over the last 100 days. The company's market cap stands at $23.1 million.
    • BioVie (NASDAQ:BIVI) stock declined by 32.27% to $6.78. BioVie's stock is trading at a volume of 3.0 million shares as of 12:30 EST. This is 341.9% of its average full-day volume over the last 100 days. The company's market cap stands at $220.1 million.
    • Axcella Health (NASDAQ:AXLA) shares decreased by 31.63% to $0.29. Axcella Health's stock is trading at a volume of 2.2 million shares as of 12:30 EST. This is 325.1% of its average full-day volume over the last 100 days. The company's market cap stands at $21.6 million.
    • Arcus Biosciences (NYSE:RCUS) stock decreased by 27.9% to $22.0. As of 12:30 EST, Arcus Biosciences's stock is trading at a volume of 2.5 million, which is 288.8% of its average full-day volume over the last 100 days. The company's market cap stands at $1.5 billion.
    • Entrada Therapeutics (NASDAQ:TRDA) stock fell 24.59% to $15.0. Entrada Therapeutics's stock is trading at a volume of 97.2K shares as of 12:30 EST. This is 146.2% of its average full-day volume over the last 100 days. The company's market cap stands at $471.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATNX
    $ATXI
    $AXLA
    $BIVI

    CompanyDatePrice TargetRatingAnalyst
    Surrozen Inc.
    $SRZN
    2/19/2026$40.00Overweight
    Cantor Fitzgerald
    Arcus Biosciences Inc.
    $RCUS
    2/12/2026$23.00Overweight → Equal Weight
    Wells Fargo
    Entrada Therapeutics Inc.
    $TRDA
    2/11/2026$20.00Buy
    Guggenheim
    Entrada Therapeutics Inc.
    $TRDA
    1/28/2026$21.00Outperform
    Oppenheimer
    Arcus Biosciences Inc.
    $RCUS
    1/13/2026$28.00Neutral → Buy
    Goldman
    Arcus Biosciences Inc.
    $RCUS
    1/8/2026$20.00Overweight → Equal-Weight
    Morgan Stanley
    Verona Pharma plc
    $VRNA
    7/14/2025Buy → Neutral
    H.C. Wainwright
    Verona Pharma plc
    $VRNA
    7/1/2025$170.00Outperform
    Wolfe Research
    More analyst ratings

    $ATNX
    $ATXI
    $AXLA
    $BIVI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tcg Crossover Gp Ii, Llc bought $1,220,362 worth of shares (48,997 units at $24.91) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    3/16/26 7:05:51 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Tcg Crossover Gp Ii, Llc bought $444,844 worth of shares (18,856 units at $23.59) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    2/13/26 4:19:53 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Tcg Crossover Gp Ii, Llc bought $202,534 worth of shares (9,357 units at $21.65) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    2/3/26 8:03:54 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATNX
    $ATXI
    $AXLA
    $BIVI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Arcus Biosciences Inc.

    SCHEDULE 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)

    3/26/26 3:45:50 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13D filed by BioVie Inc.

    SCHEDULE 13D - BIOVIE INC. (0001580149) (Subject)

    3/25/26 5:00:26 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Surrozen Inc.

    S-8 - Surrozen, Inc./DE (0001824893) (Filer)

    3/23/26 5:26:31 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATNX
    $ATXI
    $AXLA
    $BIVI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arcus Biosciences Announces New Employment Inducement Grants

    Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune disorders, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 7,050 shares of the Company's common stock at an exercise price per share of $21.41, which was the closing price on March 23, 2026, and restricted stock units to acquire a total of 3,550 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the C

    3/24/26 4:35:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Scheduled to present retinal vascular research on SZN-8141 at the upcoming 2026 ARVO Annual Meeting Received notice of achievement of research milestone by Boehringer Ingelheim for SZN-413, triggering $5 million milestone payment Strengthened key leadership roles in 2025 to support long-term ophthalmology strategy SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-t

    3/23/26 4:05:00 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioVie Announces Abstract Accepted for Presentation at AD/PD 2026

    CARSON CITY, Nev., March 12, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptance of an abstract from its SUNRISE-PD study on lead candidate bezisterim (NE3107) in the treatment of patients with Parkinson's Disease at the upcoming AD/PD 2026 Advances in Science & Therapy annual meeting, to be held March 17-21, 2026 in Copenhagen, Denmark. The abstract, titled Demographics and Baseline Characteristics of Participants in a Study of Bezisterim (NE3107) in Early Parkinson's Disease (SUNRISE-PD) (J. Palumbo1, C Ahlem1, C.L. Rea

    3/12/26 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNX
    $ATXI
    $AXLA
    $BIVI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for FAMOTIDINE issued to ATHENEX INC

    Submission status for ATHENEX INC's drug FAMOTIDINE (SUPPL-13) with active ingredient FAMOTIDINE has changed to 'Approval' on 01/07/2022. Application Category: ANDA, Application Number: 075684, Application Classification: Labeling

    1/12/22 4:41:30 AM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for KLISYRI

    Submission status for ATHENEX INC's drug KLISYRI (ORIG-1) with active ingredient TIRBANIBULIN has changed to 'Approval' on 12/14/2020. Application Category: NDA, Application Number: 213189, Application Classification: Type 1 - New Molecular Entity

    12/20/20 4:30:55 PM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNX
    $ATXI
    $AXLA
    $BIVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Tcg Crossover Gp Ii, Llc

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    3/25/26 8:02:09 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Tcg Crossover Gp Ii, Llc bought $1,220,362 worth of shares (48,997 units at $24.91) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    3/16/26 7:05:51 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Entrada Therapeutics Inc.

    4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

    3/11/26 4:35:13 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNX
    $ATXI
    $AXLA
    $BIVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Surrozen with a new price target

    Cantor Fitzgerald initiated coverage of Surrozen with a rating of Overweight and set a new price target of $40.00

    2/19/26 7:52:22 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Arcus Biosciences downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Arcus Biosciences from Overweight to Equal Weight and set a new price target of $23.00

    2/12/26 7:22:07 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Entrada Therapeutics with a new price target

    Guggenheim initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $20.00

    2/11/26 7:51:55 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNX
    $ATXI
    $AXLA
    $BIVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Arcus Biosciences Inc.

    SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

    12/17/24 9:52:58 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Avenue Therapeutics Inc.

    SC 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

    11/15/24 4:05:50 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

    SC 13G/A - Verona Pharma plc (0001657312) (Subject)

    11/14/24 5:46:11 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNX
    $ATXI
    $AXLA
    $BIVI
    Leadership Updates

    Live Leadership Updates

    View All

    Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

    Daniel Chao, M.D., Ph.D., joins Surrozen as Vice President of Clinical Development Surrozen forms Clinical Advisory Board comprised of leading retinal specialists Data Presentations at Association for Research in Vision and Ophthalmology Annual Meeting and Clinical Trials at the Summit SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. Bu

    8/8/25 4:05:56 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Entrada Therapeutics Reports Second Quarter 2025 Financial Results

    -- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple clinical trial sites in U.K. and EU activated for ELEVATE-44-201 and ELEVATE-45-201 -- -- Leadership team expanded with the additions of Navid Khan, PhD, as Senior Vice President of Medical Affairs and Kiran Patki, MD, MSc, FFPM, as Senior Vice President of Clinical Development -- -- Cash runway expected into Q2 2027 with $354 million in cash, cash equivalents and marketable securities as of June 30, 2025 -- BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) to

    8/6/25 7:00:00 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

    BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. "We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan's deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. "I'm honored to join the Board of Entrada

    6/3/25 7:00:00 AM ET
    $BIIB
    $TRDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ATNX
    $ATXI
    $AXLA
    $BIVI
    Financials

    Live finance-specific insights

    View All

    Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update

    Updated data for casdatifan in late-line kidney cancer demonstrated median progression-free survival (PFS) of 15.1 months and a confirmed overall response rate (cORR) of 45% for the 100mg once-daily (QD) cohort At least two additional data presentations for casdatifan are expected in 2026: updated data for casdatifan plus cabozantinib and initial data in early-line kidney cancer In addition to the ongoing Phase 3 PEAK-1 study, Arcus plans to initiate a Phase 3 study in the first-line (1L) metastatic setting evaluating casdatifan in a tyrosine kinase inhibitor (TKI)-free combination by the end of 2026 With $1.0 billion in cash, cash equivalents and marketable securities at year-

    2/25/26 4:05:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates

    Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will host a conference call and webcast on Wednesday, February 25th, 2026 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline update for the quarter and year ended December 31st, 2025. Investors interested in listening to the conference call may do so by dialing +1 (646) 844-6383 (local) or +1 (833) 470-1428 (toll-free), using Access Code: 190500. Participants may also register for the call onli

    2/11/26 4:05:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

    CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that a poster highlighting the design and enrichment strategy of its ongoing Phase 2 ADDRESS-LC trial will be presented at the Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes, held August 10–13 in Santa Fe, New Mexico.   Long COVID is now recognized as a leading neurological condition that has affected an estimated 400 million individuals worldwide,1,2 .The Centers for Disease Control has reported that 6.9% of adults in the United St

    8/13/25 4:05:00 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care